R Squared’s Tarsus Pharmaceuticals TARS Stock Holding History

R Squared’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-960	Closed	-$53.2K	–	1377
2024 Q4	$53.2K	Buy	+960	New	+$43.6K	0.05%	476

Other funds holding TARS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

R Squared's TARS Position: Q1 2025 in Review

R Squared sold out of Tarsus Pharmaceuticals (TARS) in Q1 2025, closing a stake of 960 shares — an estimated $53.2K sold.

R Squared first reported a position in TARS in Q4 2024 and held it in 1 quarter. The position peaked at $53.2K in Q4 2024. 194 funds tracked by Wall St. Rank hold TARS as of Q1 2025.

R Squared reported no remaining Tarsus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
R Squared sold 960 Tarsus Pharmaceuticals shares in Q1 2025, an estimated $53.2K.
R Squared first reported a position in Tarsus Pharmaceuticals in Q4 2024 and held it in 1 quarter.
R Squared's Tarsus Pharmaceuticals position peaked at $53.2K in Q4 2024.
194 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.